Urocortin 2 infusion in human heart failure

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Neuropeptide Research

Background:

• Heart failure (HF) is a complex syndrome characterized by impaired cardiac function.
• Urocortin 2 (UCN2) is a neuropeptide with potential cardiovascular effects.
• Understanding UCN2's impact on hemodynamics and neurohormonal balance in HF is crucial.

Purpose of the Study:

• To investigate the haemodynamic, neurohormonal, and renal effects of intravenous UCN2 infusion in patients with human heart failure.
• To assess dose-dependent responses to UCN2 in this population.

Main Methods:

• A single-blind, placebo-controlled, dose-escalation study.
• Eight male patients with HF (LVEF < 40%, NYHA class II-III) received placebo, low-dose (25 microg), and high-dose (100 microg) UCN2 intravenously over 1 hour.
• Hemodynamic parameters (cardiac output, LVEF, mean arterial pressure, systemic vascular resistance, cardiac work) and neurohormonal markers were monitored.

Main Results:

• UCN2 significantly increased cardiac output (CO) and left ventricular ejection fraction (LVEF) in a dose-dependent manner.
• Mean arterial pressure, systemic vascular resistance (SVR), and cardiac work (CW) were significantly reduced by UCN2.
• No significant changes were observed in vasoconstrictor/volume-retaining neurohormones.
• UCN2 led to a decrease in urinary volume but not creatinine excretion.

Conclusions:

• Intravenous UCN2 effectively improves cardiac function (CO, LVEF) and reduces hemodynamic load (SVR, CW) in patients with heart failure.
• UCN2 does not elicit significant neurohormonal responses in this context.
• The findings suggest a potential therapeutic role for UCN2 in managing heart disease, meriting further investigation.